published meta-analysis   sensitivity analysis   studies

hydroxychloroquine in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsBCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 1.15 [0.02; 58.61] COPE – Coalition V, 2022 1.56 [0.39; 6.24] COVID-PEP Severity (Skipper), 2020 1.01 [0.06; 16.28] PATCH Cohort 1 (Amaravadi), 2021 0.86 [0.02; 46.71] 1.35[0.43; 4.19]BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, COPE – Coalition V, 2022, COVID-PEP Severity (Skipper), 2020, PATCH Cohort 1 (Amaravadi), 202140%2,181moderatenot evaluable clinical deteriorationdetailed resultsPATCH Cohort 1 (Amaravadi), 2021 0.51 [0.07; 3.68] 0.51[0.07; 3.68]PATCH Cohort 1 (Amaravadi), 202110%28NAnot evaluable clinical improvementdetailed resultsCOVID-PEP Severity (Skipper), 2020 1.36 [0.87; 2.11] 1.36[0.87; 2.11]COVID-PEP Severity (Skipper), 202010%395NAnot evaluable clinical improvement (14-day)detailed resultsCOVID-PEP Severity (Skipper), 2020 1.36 [0.87; 2.11] 1.36[0.87; 2.11]COVID-PEP Severity (Skipper), 202010%395NAnot evaluable hospitalizationdetailed resultsBCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 0.75 [0.32; 1.76] COPE – Coalition V, 2022 0.77 [0.52; 1.13] PATCH Cohort 1 (Amaravadi), 2021 1.79 [0.06; 57.93] 0.77[0.55; 1.10]BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, COPE – Coalition V, 2022, PATCH Cohort 1 (Amaravadi), 202130%1,694moderatenot evaluable mechanical ventilationdetailed resultsCOPE – Coalition V, 2022 1.32 [0.46; 3.79] 1.32[0.46; 3.79]COPE – Coalition V, 202210%1,369NAnot evaluable ICU admissiondetailed resultsCOPE – Coalition V, 2022 0.84 [0.43; 1.63] 0.84[0.43; 1.63]COPE – Coalition V, 202210%1,369NAnot evaluable adverse eventsdetailed resultsOut of scaleBCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 178.20 [73.71; 430.85] COVID-PEP Severity (Skipper), 2020 2.75 [1.80; 4.21] 21.73[0.36; 1295.07]BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, COVID-PEP Severity (Skipper), 2020299%776moderatenot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-03-28 13:22 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 657,832 - roots T: 290